Suganuma Y, Ise T, Akiyama Y, Bessho F, Fukazawa K, Hirotsu T, Kitamura T, Koide A, Matsuyama K, Muchi H
Dept. of Pediatric Surgery, Hachioji Children's Hospital.
Gan To Kagaku Ryoho. 1987 Nov;14(11):3083-90.
A cooperative multicenter clinical study on cisplatin in children with malignant solid tumors was conducted in seventeen institutions. Of 63 children entered into the study, 18 patients were treated with cisplatin alone, 33 with a VCAP regimen (VCR, CPA, ADM and CDDP) and 12 with other combination regimens. The numbers of evaluable patients were 14, 27 and 7, respectively. Response rates for neuroblastoma were 37.5% (3/8) with cisplatin alone and 79.2% (19/24) for the VCAP regimen. Major adverse effects were gastrointestinal symptoms, bone marrow suppression and renal impairment. Hearing difficulty, electrolyte imbalance and transient elevation of transaminase were also observed. However, these adverse effects were within a tolerable range of severity. The results of this study demonstrate that cisplatin is a useful drug in the treatment of neuroblastoma.
一项关于顺铂治疗儿童恶性实体瘤的多中心合作临床研究在17家机构开展。在63名进入该研究的儿童中，18例患者仅接受顺铂治疗，33例采用VCAP方案（长春新碱、环磷酰胺、阿霉素和顺铂）治疗，12例采用其他联合方案治疗。可评估患者数量分别为14例、27例和7例。顺铂单药治疗神经母细胞瘤的缓解率为37.5%（3/8），VCAP方案的缓解率为79.2%（19/24）。主要不良反应为胃肠道症状、骨髓抑制和肾功能损害。还观察到听力困难、电解质失衡和转氨酶短暂升高。然而，这些不良反应的严重程度在可耐受范围内。本研究结果表明，顺铂是治疗神经母细胞瘤的一种有效药物。
